2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - R02-R05
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MPN, CML, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human
PAPER

1077 Subjective and objective sleep quality in hospitalized adults with acute leukemia: A quality improvement study

Michelle Yu Zhang, MD, Kathryn (Katie) D. Russell, ARNP2, Kate Ramsower3, Alexi Vasbinder4, Carole Shaw5, Tim Monahan6, Madison Frieler, PA-C7, Roland Bruno Walter, MD, PhD, MS8, Anna Halpern, MD9
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background: Impaired sleep in hospitalized patients is associated with adverse health outcomes, but data in adult cancer patients are sparse. Patients with acute leukemia (AL) are frequently hospitalized and at high risk of disrupted sleep from overnight vital sign (VS) checks, lab draws, chemotherapy administration, and transfusion of blood products. We aimed to better quantify subjective and objective sleep quality in hospitalized AL patients as the first part of a quality improvement (QI) study to improve sleep quality and duration in this population.

Methods: This prospective observational study at University of Washington included 3 cohorts of hospitalized adult AL patients: patients receiving intensive chemotherapy (A), patients admitted for febrile neutropenia ([FN], B) and patients receiving supportive care following chemotherapy (C).  After enrollment, patients completed daily sleep questionnaires and were provided a wearable Fitbit (Inspire 3). Other outcomes were collected via the electronic medical record (EMR). Patients were followed for 7 days or until discharge.

The primary objective was to evaluate daily subjective sleep quality as measured by the Richards-Campbell Sleep Questionnaire ([RCSQ]), a validated 5-item sleep assessment tool. Each question is scored from 0-100; a score of 0-25 correlates with very poor sleep, 26-50 with poor sleep, 51-75 with good sleep, and 76-100 with very good sleep. The total score is a mean of 5 items, plus a score for noise. Secondary objectives included estimating median sleep duration using Fitbits, frequency of nighttime VS (10PM-6AM), and feasibility. Feasibility was defined as completed RCSQ and Fitbit data transmission in ≥50% of patient days on study. We planned to enroll 20 subjects in each arm.

Results: Forty-eight patients were enrolled (cohort A: n=20; cohort B: n=8; cohort C: n=20) from 5/2025-5/2026. The median (range) age was 50.5 (22-77) years, 65% male, 79% had AML/high-grade MDS, 21% ALL. The median (range) time on study was 7 (1-7) days.  

The median total RCSQ score was 49.4 (range 0-100) correlating with generally poor perceived sleep quality, with similar scores across cohorts. Generally, sub-scores showed poor sleep depth (median 41.5), good sleep latency (57.0), and relatively minimal noise (71.0) as well as neutral ratings on duration of awakenings (50.0), ability to return to sleep (50.0) and overall sleep quality (50.0).  Subjective sleep quality (total RCSQ score) was not significantly associated with cohort, age, disease type, or ethnicity in multivariable linear regression.

Based on Fitbit data, the median (range) sleep duration was 7.1 hours (0.7-16.9) per 24 hours and 6.8 hours (0.9-12.1) per night. Sleep duration per night did not differ between cohort A (6.4 hours, ref), B (6.8 hours, p= 0.73), and C (6.9 hours, p=0.86). Daytime napping (8AM- 6PM) occurred in 31% of patient days, for a median (range) of 88 (25-389) minutes. Per patient, the RCSQ and objective sleep duration were only weakly correlated (rho 0.22, p=0.25).  There was a median of 3 VS checks (range 1-34)/night; 23.0% of nights had ≥5 VS checks. There was no significant difference in median VS disruptions between cohorts.

With a 64% RCSQ survey completion rate, the study was found to be feasible (completion rates by cohort: A = 62%, B=54%, C= 68%). Additionally, Fitbit data transmission was successful with data available for 61% of patient days on study (cohort A=59%, B = 52%, C= 66%).  It was not feasible to fully enroll in FN cohort B, as patients with fevers frequently had medical comorbidities precluding participation.

Conclusions: Patients with AL hospitalized for chemotherapy, FN and post-induction monitoring have poor sleep quality and sleep depth despite a median of 6.8 hours of sleep per night. There were frequent interruptions for VS that were similar for all cohorts despite differences in clinical stability. With limited numbers, we found no association between subjective sleep quality and objective sleep duration. We found it feasible to assess subjective sleep quality via daily RCSQ (one of the first uses of this survey in this population) and to quantify sleep duration via Fitbit in AL patients hospitalized for chemotherapy or monitoring.  As the next step, we will evaluate an intervention to improve inpatient sleep in low-risk hospitalized patients with AL by minimizing disruptions via a remote temperature monitor.

Michelle Yu Zhang, MD: No relevant conflicts of interest to declare.